The global pharmacogenomic market is expected to reach to grow with the CAGR of 8%-10% by 2025

   January 13, 2021
According to a new market report published by Lucintel, the future of the pharmacogenomic market looks promising with opportunities in cardiovascular diseases, infectious diseases, oncology, neurological diseases, psychiatry, and pain management. The global pharmacogenomic market is expected to grow with a CAGR of 8%-10% from 2020 to 2025. The major drivers for this market are increasing prevalence of several infectious and non-infectious diseases, rising usage in drug discovery processes, increasing demand for personalized drugs, and growing awareness of the benefits associated with pharmacogenomics.

Pharmacogenomics is the study of the role of the genome in drug response. In this market, sequencing, polymerase chain reaction, gel electrophoresis, mass spectrometry, and microarray are the major technology segments. Lucintel forecasts that polymerase chain reaction will remain the largest technology segment over the forecast period due to its irreplaceability in terms of use for the amplification of a small segment of DNA.

Within this market, hospitals and clinics will remain the largest end user segment over the forecast period due to better infrastructure and technological edge over other medical centers and the presence of highly skilled medical professionals and patients.

North America will remain the largest region over the forecast period due to increasing usage of pharmacogenomics in the development of more potent as well as personalized medicines and high awareness among physicians and drug developers of the benefits of pharmacogenomics, such as increased reliability and reduced side effects.

Affymetrix, AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Bayer, Merck, GlaxoSmithKline, Johnson & Johnson, Myriad Genetics, and Pathway Genomics Corporation are among the major suppliers in the global pharmacogenomic market.

Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global pharmacogenomic market by technology, application, end user, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Pharmacogenomic Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global pharmacogenomic market by technology, application, end user, and region as follows:

By Technology [Value ($ Million) shipment analysis for 2014 – 2025]:

  • Sequencing

  • Polymerase Chain Reaction

  • Gel Electrophoresis

  • Mass Spectrometry

  • Microarray

  • Others


By Application [Value ($ Million) shipment analysis for 2014 – 2025]:

  • Cardiovascular Diseases

  • Infectious Diseases

  • Oncology

  • Neurological Diseases

  • Psychiatry

  • Pain Management

  • Others


By End User [Value ($ Million) shipment analysis for 2014 – 2025]:

  • Hospitals & Clinics

  • Research Institutions and Academic Institutes

  • Others

By Region [Value ($ Million) shipment analysis for 2014 – 2025]:

  • North America

  • United States

  • Canada

  • Mexico

  • Europe

  • United Kingdom

  • Spain

  • Germany

  • France

  • Asia Pacific

  • China

  • India

  • Japan

  • The Rest of the World

  • Brazil


This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at

About Lucintel

Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit

Lucintel Corporate Customers

Market Entry, M & A, Opportunity Screening,...

Private Equity Customers

Buy Side Services (target screening, due diligence, ..)

Customer Quotes

"With more than 20 years experience in the industry, this is the first time we have come across such an extensive market analysis for our industry." Ven Cote, CEO, ZCL

"The insights we gained from Lucintel work helped with our business plan…a wonderful professional job…" Mike Jackson, Stahlin

"The report from Lucintel is useful not only for business planners, but also for the technology officers wanting to create a roadmap …" Dr. Giulio Ranzo, Booz Allen

"The information is so comprehensive, it has allowed us to identify & focus our business development efforts. It saved months of leg-work." Bill Barz, L&L Products

"We bought Lucintel report because it is the best report about our industry…a complete and appropriate analysis." Cesare Andrenacci, Ferretti